Throughout the last three months, 4 analysts have evaluated Definitive Healthcare DH, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 0 | 3 | 0 | 0 |
Last 30D | 1 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 2 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $9.88, a high estimate of $11.00, and a low estimate of $9.00. Experiencing a 4.82% decline, the current average is now lower than the previous average price target of $10.38.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Definitive Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
David Grossman | Stifel | Lowers | Buy | $9.50 | $11.00 |
Craig Hettenbach | Morgan Stanley | Lowers | Equal-Weight | $9.00 | $11.50 |
Saket Kalia | Barclays | Raises | Equal-Weight | $11.00 | $10.00 |
David Hayes | Canaccord Genuity | Raises | Hold | $10.00 | $9.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Definitive Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Definitive Healthcare compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Definitive Healthcare's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Definitive Healthcare's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Definitive Healthcare analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Definitive Healthcare
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. The company's solutions provide accurate and comprehensive information on healthcare providers and their activities to help customers optimize everything from product development to go-to-market planning and sales and marketing execution. Geographically, it derives a majority of its revenue from the United States.
Breaking Down Definitive Healthcare's Financial Performance
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Definitive Healthcare showcased positive performance, achieving a revenue growth rate of 8.8% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -15.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Definitive Healthcare's ROE excels beyond industry benchmarks, reaching -1.19%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Definitive Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of -0.56%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Definitive Healthcare's debt-to-equity ratio is below the industry average. With a ratio of 0.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.